The U.S. Food and Drug Administration (FDA) said on Tuesday it will restructure its food program that was slammed last year for responding too slowly to an outbreak of illness among infants who consumed formula from an Abbott Laboratories production plant.

The company is cutting 6% from its non-clinician global workforce, as it plans to prioritize its commercial businesses in a challenging demand environment.

The job cuts will span three business units – Novartis Pharmaceuticals, Novartis Services Inc., and Novartis Corporation – with terminations taking effect on January 28, 2023.

Pittsburgh-based NeuBase is diverting resources from its Huntington’s program and shedding 60% of its workforce in a strategic restructuring, the company announced Friday. 

Novartis said on Thursday that it would cut up to 400 jobs in Ireland, or about a quarter of its workforce there, as part of a previously announced restructuring program that will cut 8,000 jobs globally.

Rare disease biotech BioMarin Pharmaceuticals Inc. announced Friday it was shedding around 4% of its global workforce, or around 120 jobs, in an effort to improve its operational efficiency.

As the economy ebbs and flows, pharma and biotech companies alike are feeling the pressure to cut costs. From rapid inflation to the ever-changing regulatory landscape, many are looking for ways to reduce their burn rate.

Cancer immunotherapy biotech OncoSec Medical Inc. will lay off around 45% of its workforce to focus its resources on the development of its lead asset, TAVO-EP (tavokinogene telseplasmid), the company announced Tuesday.

The U.S. Centers for Disease Control and Prevention said it will prioritize its public health response in a revamp of its structure after months of criticism over its handling of the COVID-19 and monkeypox pandemics.

Adverum Biotechnologies announced Thursday that it is removing 78 jobs, slashing its workforce by 38%. This move is in line with the company’s plan to streamline operations in order to completely fund existing eye disease projects and extend its cash runway into 2025.